These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 19549896)

  • 1. Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition.
    Racanelli AC; Rothbart SB; Heyer CL; Moran RG
    Cancer Res; 2009 Jul; 69(13):5467-74. PubMed ID: 19549896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas.
    Rothbart SB; Racanelli AC; Moran RG
    Cancer Res; 2010 Dec; 70(24):10299-309. PubMed ID: 21159649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AMP-activated Protein Kinase (AMPK) Control of mTORC1 Is p53- and TSC2-independent in Pemetrexed-treated Carcinoma Cells.
    Agarwal S; Bell CM; Rothbart SB; Moran RG
    J Biol Chem; 2015 Nov; 290(46):27473-86. PubMed ID: 26391395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pemetrexed: from preclinic to clinic].
    Lansiaux A; Lokiec F
    Bull Cancer; 2007; 94 Spec No Actualites():S134-8. PubMed ID: 17845983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pemetrexed disodium.
    Gibbs D; Jackman A
    Nat Rev Drug Discov; 2005 May; Suppl():S16-7. PubMed ID: 15962527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemetrexed: a multitargeted antifolate.
    Rollins KD; Lindley C
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pemetrexed (Alimta): a novel multitargeted antifolate agent.
    Adjei AA
    Expert Rev Anticancer Ther; 2003 Apr; 3(2):145-56. PubMed ID: 12722874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
    Sengupta TK; Leclerc GM; Hsieh-Kinser TT; Leclerc GJ; Singh I; Barredo JC
    Mol Cancer; 2007 Jul; 6():46. PubMed ID: 17623090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pemetrexed and its emerging role in the treatment of thoracic malignancies.
    Scagliotti GV; Novello S
    Expert Opin Investig Drugs; 2003 May; 12(5):853-63. PubMed ID: 12720495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors.
    Hanauske AR; Chen V; Paoletti P; Niyikiza C
    Oncologist; 2001; 6(4):363-73. PubMed ID: 11524555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer.
    Scagliotti GV; Selvaggi G
    Clin Lung Cancer; 2008; 9 Suppl 3():S122-8. PubMed ID: 19419926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemetrexed disodium, a novel antifolate with multiple targets.
    Curtin NJ; Hughes AN
    Lancet Oncol; 2001 May; 2(5):298-306. PubMed ID: 11905785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pemetrexed: an active new agent for breast cancer.
    O'Shaughnessy JA
    Semin Oncol; 2002 Dec; 29(6 Suppl 18):57-62. PubMed ID: 12571813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pemetrexed (Alimta, MTA, multitargeted antifolate, LY231514) for malignant pleural mesothelioma.
    Manegold C
    Semin Oncol; 2003 Aug; 30(4 Suppl 10):32-6. PubMed ID: 12917819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors.
    Adjei AA
    Ann Oncol; 2000 Oct; 11(10):1335-41. PubMed ID: 11106124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmentation of reduced folate carrier-mediated folate/antifolate transport through an antiport mechanism with 5-aminoimidazole-4-carboxamide riboside monophosphate.
    Visentin M; Zhao R; Goldman ID
    Mol Pharmacol; 2012 Aug; 82(2):209-16. PubMed ID: 22554803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pemetrexed disodium for the treatment of NSCLC: an update.
    Hsu JY; Wakelee H
    Drugs Today (Barc); 2008 Sep; 44(9):669-78. PubMed ID: 19137122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pemetrexed: current development and future directions in thoracic cancers.
    Manegold C
    Suppl Tumori; 2002; 1(4):S11-2. PubMed ID: 12415805
    [No Abstract]   [Full Text] [Related]  

  • 19. Pemetrexed: a new cytotoxic agent in the development for first-line non-small-cell lung cancer.
    Scagliotti GV
    Lung Cancer; 2005 Oct; 50 Suppl 1():S18-9. PubMed ID: 16291426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer.
    Shimizu T; Nakanishi Y; Nakagawa Y; Tsujino I; Takahashi N; Nemoto N; Hashimoto S
    Anticancer Res; 2012 Oct; 32(10):4589-96. PubMed ID: 23060591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.